霉浆菌检测市场 - 全球产业规模、份额、趋势、机会及预测（按产品、技术、应用、最终用户、地区和竞争格局划分），2021-2031年

全球霉浆菌检测市场预计将从 2025 年的 10.9792 亿美元成长到 2031 年的 23.4842 亿美元，复合年增长率为 13.51%。

霉浆菌检测涉及一系列分析通讯协定，旨在识别细胞库、原料和成品生物製药产品中的支原体污染，以确保病患安全。该市场的主要驱动力是生物製药产量的成长以及严格的监管要求，这些要求规定产品在上市前必须不含外来性物质。此外，需要严格品质保证的先进治疗药物的商业性化也成为重要的成长引擎。根据再生医学联盟发布的2025年报告，全球细胞和基因疗法收入的35%将来自美国以外地区，凸显了生物製药产业的国际化程度，而这需要强大的检测能力。

儘管市场需求强劲，但由于检验旨在取代传统28天培养法的快速替代方法面临监管方面的困难，成长受到阻碍。製造商在证明更快速、自动化的技术能够达到与既定药典标准相当的检测极限方面，常常面临重大挑战。这些检验难题往往会延缓高效检测方案在保质期短的治疗药物中的应用。

市场驱动因素

全球对生物製药和生物相似药日益增长的需求是霉浆菌检测市场的主要驱动力，从根本上改变了品管标准。随着製药开发商竞相将复杂的分子商业化，为保障患者健康，强制性批次放行检测中对外来性的病原体进行检测的需求也相应增长。监管机构的持续行动也支持了这一趋势。例如，Fierce Pharma在2026年1月通报称，美国FDA药物评估与研究中心在2025年核准了46种新药。这些新治疗方法的不断涌现需要严格的无菌检验和扩展的检测通讯协定，以最大限度地降低产品生命週期内的污染风险。

同时，生物製药生产能力的显着扩张正在推动市场成长，各公司纷纷升级基础设施以满足全球供应需求。新的生产基地需要进行全面的验证，包括公用设施监测和原材料分析，这导致霉浆菌检测方法的使用量显着增加。例如，安进公司在2025年9月的新闻稿中宣布，将投资6.5亿美元扩大在美国的生产网络，并建立需要生物安全监测的新营运基地。此外，这种扩张也体现在契约製造业。三星生物製剂公司在2025年7月发布的「2025年第二季财务业绩报告」显示，该公司在上半年获得了价值24亿美元的生产合同，凸显了其庞大的生产规模，而这依赖于完善的检测策略。

市场挑战

与评估替代快速检测技术相关的监管复杂性严重阻碍了全球霉浆菌检测市场的成长。儘管製造商寻求引入自动化快速检测技术以取代传统的28天培养方法，从而加快保质期短的治疗药物的上市，但监管机构却提出了严格的可比性要求。企业必须证明这些快速检测方法的检测极限与既定的药典通讯协定无法区分。这项规定需要耗费大量成本和时间检验研究，这往往会延缓快速检测系统的应用，并抑制高价值快速检测耗材的持续销售。

这些营运障碍阻碍了市场充分利用生物製药产业的扩张。根据再生医学联盟的数据，预计到2025年，全球治疗药物研发公司的数量将增加6%。虽然这表明测试解决方案的基本客群正在扩大，但繁琐的检验程序却阻碍了研发人员转向更先进的调查方法。因此，製造商被迫依赖过时且缓慢的测试流程，而不是采用能够提升市场价值的优质快速解决方案，从而延缓了市场收入的累积。

市场趋势

从基于培养的方法向核酸扩增技术 (NAT) 的转变正在加速。这主要是由于生物製药产业迫切需要快速批次放行。传统的 28 天培养检测对于保质期有限的治疗药物而言已成为瓶颈，因此製造商正在转向分子生物学方法，这些方法在提供相当灵敏度的同时，显着缩短了周转时间。现代检测方法的性能充分体现了这种操作方式的转变。如同 Eurofins 2025 年 6 月发布的《生物製药服务新闻 - 2025 年夏季刊》中所述，检验的NAT 平台（例如 MycoSEQ）可在不到五天内提供霉浆菌检测的确认结果。检测时间的显着缩短使生物製药开发商能够在遵守严格安全法规的同时，加快产品放行计画。

同时，随着越来越多的公司寻求为复杂的商业化阶段试验提供专门的基础设施，对受託研究机构(CRO) 的日益依赖正在重塑市场格局。生物製药开发商正透过利用提供一体化生产和品管服务的外部合作伙伴来简化其供应链，从而避免扩大自有实验室所需的大量资本投资。这种策略整合趋势在近期的产业发展中显而易见。 2025年5月，Minaris Advanced Therapies在ISCT年会上发布新闻稿，宣布“新公司成立”，并表示该公司已将Minaris Regenerative Medicines与无锡先进疗法株式会社的美国和英国分部合併。此次合併创建了一个全球性组织，为超过27种商业产品提供测试服务，显示市场对大型综合测试服务提供者的依赖程度日益加深。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球霉浆菌检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（仪器、试剂盒、试剂）
  • 透过技术（PCR、ELISA、酵素法、DNA染色等）
  • 按应用领域（细胞株测试、生物生产测试等）
  • 按最终用户（学术研究机构、细胞库、合约研究组织、製药/生物技术公司等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美霉浆菌检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲霉浆菌检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区霉浆菌检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲霉浆菌检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美霉浆菌检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球霉浆菌检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Mycoplasma Testing Market is projected to expand from USD 1097.92 Million in 2025 to USD 2348.42 Million by 2031, reflecting a compound annual growth rate (CAGR) of 13.51%. Mycoplasma testing involves analytical protocols designed to identify Mollicutes contamination within cell banks, raw materials, and finished biopharmaceutical goods to guarantee patient safety. This market is chiefly bolstered by the rising quantity of biopharmaceutical production and strict regulatory requirements mandating that products remain free of adventitious agents before release. Additionally, the commercial introduction of advanced therapeutic medicinal products, which necessitate stringent quality assurance, serves as a key growth engine. As reported by the Alliance for Regenerative Medicine in 2025, 35% of global revenue derived from cell and gene therapies originated outside the United States, highlighting the broadening international scope of the biologics industry that demands extensive testing frameworks.

Despite strong market demand, growth is hindered by the regulatory difficulties involved in validating rapid alternative methods intended to supersede traditional 28-day culture assays. Manufacturers frequently encounter significant obstacles in proving that faster, automated technologies offer detection limits equivalent to established compendial standards. These validation challenges often postpone the integration of efficient testing solutions for therapies with short shelf lives.

Market Driver

The escalating global requirement for biologics and biosimilars serves as a primary propellant for the mycoplasma testing market, fundamentally altering quality control standards. As pharmaceutical developers hasten the commercial launch of complex molecules, the necessity for mandatory lot release testing for adventitious agents increases proportionally to safeguard patient health. This pattern is confirmed by persistent regulatory momentum; for instance, Fierce Pharma reported in January 2026 that the U.S. FDA's Center for Drug Evaluation and Research authorized 46 novel drugs in 2025. This continuous arrival of new therapies necessitates rigorous sterility verification and expanded testing protocols to minimize contamination risks throughout the product's life cycle.

Concurrently, the substantial enlargement of biopharmaceutical manufacturing capabilities drives market growth, as corporations upgrade infrastructure to satisfy global supply demands. New production sites mandate comprehensive validation, encompassing utility monitoring and raw material analysis, which markedly boosts the usage of mycoplasma detection assays. To demonstrate this investment trend, Amgen announced in a September 2025 press release that it had dedicated $650 million to extending its U.S. manufacturing network, thereby establishing new operational hubs that require biosafety oversight. Moreover, the outsourcing industry reflects this expansion; according to Samsung Biologics' 'Second Quarter 2025 Financial Results' released in July 2025, the firm obtained sales contracts amounting to $2.4 billion in the first half of the year, emphasizing the massive scale of manufacturing operations dependent on robust testing strategies.

Market Challenge

The regulatory intricacies tied to validating rapid alternative techniques notably obstruct the growth of the Global Mycoplasma Testing Market. While manufacturers aim to supersede traditional 28-day culture assays with accelerated automated technologies to speed up the release of short-shelf-life treatments, regulatory bodies impose rigorous comparability requirements. Companies must demonstrate that these rapid methods attain detection limits indistinguishable from established compendial protocols. This stipulation leads to costly and prolonged validation studies, which often postpone the deployment of faster testing systems and curtail recurring sales of high-value rapid testing consumables.

This operational impediment hinders the market from fully leveraging the broader expansion of the biopharmaceutical industry. Data from the Alliance for Regenerative Medicine indicates that the global count of therapeutic developers rose by 6% in 2025. While this suggests a growing client base for testing solutions, the onerous validation procedure deters these developers from transitioning to advanced methodologies. As a result, the market undergoes retarded revenue accumulation because manufacturers are compelled to depend on slower, legacy testing processes instead of embracing premium rapid solutions that would enhance market value.

Market Trends

The shift from culture-based techniques to Nucleic Acid Amplification Techniques (NAT) is gaining momentum, fueled by the urgent necessity for rapid lot release in biomanufacturing. Since traditional 28-day culture assays generate bottlenecks for therapeutics with limited shelf lives, manufacturers are turning to molecular alternatives that provide equivalent sensitivity with drastically shortened turnaround times. This operational transition is highlighted by the performance of contemporary assays; as noted in Eurofins' 'BioPharma Services News - Summer 2025' report from June 2025, validated NAT platforms like MycoSEQ are capable of delivering confirmed mycoplasma detection results in fewer than five days. This significant decrease in testing time enables biopharmaceutical developers to accelerate product release schedules while adhering to rigorous safety regulations.

At the same time, the rising reliance on outsourcing to Contract Research Organizations (CROs) is restructuring the market environment, as companies pursue specialized infrastructure for intricate commercial-stage testing. Biopharmaceutical developers are streamlining their supply chains by engaging external partners who provide unified manufacturing and quality control services, thereby circumventing the steep capital expenditures associated with internal lab expansion. This movement toward strategic consolidation is exemplified by recent industry developments; according to a May 2025 press release by Minaris Advanced Therapies regarding the 'New company unveiled at the annual ISCT conference,' the firm merged Minaris Regenerative Medicine with the U.S. and U.K. divisions of WuXi Advanced Therapies. This union created a global entity managing testing services for more than 27 commercial products, underscoring the sector's increasing dependence on large-scale, integrated testing providers.

Key Market Players

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

Report Scope

In this report, the Global Mycoplasma Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mycoplasma Testing Market, By Product

• Instruments
• Kits and Reagents

Mycoplasma Testing Market, By Technology

• PCR
• ELISA
• Enzymatic Methods
• DNA Staining
• Other

Mycoplasma Testing Market, By Application

• Cell Line Testing
• Bioproduction Testing
• Other

Mycoplasma Testing Market, By End-User

• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

Mycoplasma Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mycoplasma Testing Market.

Available Customizations:

Global Mycoplasma Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Mycoplasma Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Kits and Reagents)
  • 5.2.2. By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other)
  • 5.2.3. By Application (Cell Line Testing, Bioproduction Testing, Other)
  • 5.2.4. By End-User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Mycoplasma Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Mycoplasma Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Mycoplasma Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Mycoplasma Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-User

7. Europe Mycoplasma Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Mycoplasma Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Mycoplasma Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Mycoplasma Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Mycoplasma Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Mycoplasma Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-User

8. Asia Pacific Mycoplasma Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Mycoplasma Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Mycoplasma Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Mycoplasma Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Mycoplasma Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Mycoplasma Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Mycoplasma Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Mycoplasma Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Mycoplasma Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Mycoplasma Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-User

10. South America Mycoplasma Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Mycoplasma Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Mycoplasma Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Mycoplasma Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Mycoplasma Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ATCC
• 15.3. Bionique Testing Laboratories Inc.
• 15.4. Charles River Laboratories International Inc.
• 15.5. Lonza Group Ltd
• 15.6. Merck KGaA
• 15.7. Bionique Testing Laboratories Inc.
• 15.8. PromoCell GmbH
• 15.9. Thermo Fisher Scientific Inc.
• 15.10. Sartorius AG

16. Strategic Recommendations

17. About Us & Disclaimer